Jaguar Health, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Jaguar Health, Inc. on October 29, 2018. The Company is an emerging growth company incorporated in Delaware, focused on the development and commercialization of Mytesi (crofelemer), its first-in-class, FDA-approved anti-secretory human prescription drug.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves as a notification of an upcoming event rather than a financial statement.
Material Changes
No material financial changes or operational updates were disclosed in this specific filing. The report solely announces the scheduling of a future conference call.
Guidance, Outlook, and Management Commentary
Management has scheduled a conference call for Thursday, November 15, 2018, at 8:00 a.m. ET / 5:00 a.m. PT. The call will cover:
- Third quarter 2018 financial results.
- Current and planned commercial, educational, and product development activities for Mytesi.
- An education session regarding the distinct first-in-class mechanism of action of Mytesi.
A press release detailing this announcement is included as Exhibit 99.1.
Investor Verification Checklist
- Verify the date and time of the Q3 2018 earnings conference call (November 15, 2018).
- Review the attached press release (Exhibit 99.1) for any additional context not included in the 8-K body.
- Monitor the upcoming earnings release for actual financial performance data, as none is present in this filing.
- Confirm the Company's status as an emerging growth company and its election regarding extended transition periods for accounting standards.